Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Brain Neoplasms 593Glioblastoma 573Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Recurrence 56Melanoma 56Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemangiopericytoma × CNS × Clear all
NCT03016091 2025-02-18

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Rabin Medical Center

Phase 2 Terminated
18 enrolled 9 charts
CNS

Hemangiopericytoma, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡